Elsevier

Neurologic Clinics

Volume 20, Issue 4, November 2002, Pages 1125-1141
Neurologic Clinics

Review article
Rett syndrome: Current status and new vistas

https://doi.org/10.1016/S0733-8619(02)00022-1Get rights and content

Section snippets

Clinical characteristics

RS (Fig. 1) is characterized by profound cognitive impairment, communication dysfunction, stereotypic movements, and pervasive growth failure, which follow a period of apparently normal development for the first 6 to 18 months of life [9]. All attempts to find a biologic marker were unsuccessful until the recent identification of a gene for RS [10]. The diagnosis of RS, however, is based on clinical criteria (Table 2) [11], [12], because not all girls with the RS phenotype have mutations in

Clinical staging

RS has been characterized in four clinical stages [14], providing a format for plotting clinical progression. The transition from one stage to the next is generally along a continuum rather than an abrupt change. The first stage is the early-onset stagnation period, which occurs from the age of 6 to 18 months. Usually, this stage lasts weeks to months and consists of delay in developmental progress but no clear evidence of regression. The second stage is that of rapid developmental regression

Variant phenotypic expression

Variant phenotypic expressions of RS are well described. The so-called forme fruste is the most common, consisting of delay in onset until the age of 8 to 10 years [15]. Other atypical forms include a preserved speech variant [16], a congenital form in which no period of developmental progress is noted, and an early-onset seizure form [17]. The relatively severe epileptic encephalopathy of the early-onset seizure form results in little or no normal early development.

Hagberg and Skjeldal [18]

Rett syndrome in boys and men

Convincing descriptions of boys and men with RS are limited. RS has been described in boys with more than one X chromosome (Klinefelter syndrome [XXY]) [19], [20], [21], [22]. Alternatively, mutations in MECP2 have been identified in male patients with features quite different from those of RS. These include individuals with a rapidly progressive encephalopathy [19], [23], [24], [25], severe developmental delay [26], [27], [28], spastic paraparesis [29], and nonspecific mental retardation [30],

Specific clinical issues

Several specific clinical issues should be noted. These include longevity, cognitive impairment, seizures, breathing irregularities, scoliosis, ambulation, growth failure, gastrointestinal function, and self-abuse. In general, survival is quite prolonged, and growth failure is pervasive.

Long-term management

Presently, long-term management of girls with RS involves appropriate physical and occupational therapy, speech therapy, nutritional support, orthopedic intervention, and seizure control [9], [32]. As noted previously, the potential longevity of women with RS requires long-term planning, because the parents may not be able to manage these needs as they age.

Neuropathology

The characteristic neuropathologic findings in RS consist of reduced brain weight, reduced volume of frontal cortex and deep gray nuclei, reduced melanin deposition in the substantia nigra, smaller neurons, reduced dendritic arborizations, and the absence of any recognizable disease process, particularly a progressive neurodegenerative disorder [54], [55], [56], [57], [58]. As such, the fundamental neurobiologic mechanism seems to be an arrest in normal neuronal maturation, giving RS the

Genetic basis of Rett syndrome

RS is a genetic disorder predominantly affecting girls and women and is transmitted in an X-linked dominant fashion with presumed lethality in boys and men. RS is sporadic in more than 99% of affected girls and women; that is, recurrence within families is less than 1%. Thus, for the most part, RS represents new mutations.

Despite the small number of familial cases, linkage studies were able to focus attention to Xq28, a gene-rich region [64], [65]. As a result, mutations were identified in the

MeCP2 function in developmental neurobiology

MeCP2 plays an important role in transcriptional silencing, yet its precise relation to developmental neurobiology is largely unknown [90]. The association of the gene encoding MeCP2 with RS has provided new impetus for such studies. MeCP2 functions in transcriptional silencing by binding to methylated CpG dinucleotides in gene promoter regions. In the mammalian genome, 60% to 90% of the cytosine residues in CpG dinucleotides are methylated, a process established during early embryonic

Summary

RS, the most common cause of profound cognitive impairment in girls and women, is composed of characteristic clinical features, including communication dysfunction, stereotypic movements, and pervasive growth failure. Neuropathologic findings indicate a failure of neuronal maturation with too small neurons and too few dendritic arbors and no evidence of a progressive neurodegenerative process. The combination of clinical and neuropathologic characteristics presents the profile of a

First page preview

First page preview
Click to open first page preview

References (101)

  • C.J Phiel et al.

    Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

    J Biol Chem

    (2001)
  • E Lugaresi et al.

    Abnormal breathing in the Rett syndrome

    Brain Dev

    (1985)
  • D.J Harrison et al.

    Scoliosis in the Rett syndrome: natural history and treatment

    Brain Dev

    (1990)
  • V.A Holm et al.

    Scoliosis in the Rett syndrome

    Brain Dev

    (1990)
  • K Motil et al.

    Increased energy expenditure associated with repetitive involuntary movement does not contribute to growth failure in girls with Rett syndrome

    J Pediatr

    (1998)
  • D Armstrong et al.

    Organ growth in Rett syndrome: a postmortem examination analysis

    Pediatr Neurol

    (1999)
  • S Takashima et al.

    Dendrites, dementia and the Down syndrome

    Brain Dev

    (1989)
  • I.M Buyse et al.

    Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms

    Am J Hum Genet

    (2000)
  • I.B Van den Veyver et al.

    Methyl-CpG-binding protein 2 mutations in Rett syndrome

    Curr Opin Genet Dev

    (2000)
  • K Inui et al.

    Mutational analysis of MECP2 in Japanese patients with atypical Rett syndrome

    Brain Dev

    (2001)
  • A.P Bird

    Gene number, noise reduction and biological complexity

    Trends Genet

    (1995)
  • Y Feng et al.

    FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association

    Mol Cells

    (1997)
  • S.T Warren et al.

    Trinucleotide repeat expansions in neurological disease

    Curr Opin Neurobiol

    (1993)
  • A Rett

    Uber ein eigenartiges hirnatrophisches Syndrom bei Hyperammonamie im Kindesalter

    Wien Med Wochenschr

    (1966)
  • B Hagberg et al.

    A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases

    Ann Neurol

    (1983)
  • V.A Holm

    Rett's syndrome: a progressive developmental disability in girls

    Dev Behav Pediatr

    (1985)
  • A.M Kerr et al.

    A study of the natural history of Rett syndrome in 23 girls

    Am J Med Genet

    (1986)
  • A.K Percy et al.

    Rett syndrome: initial experience with an emerging clinical entity

    Brain Dev

    (1985)
  • B.A Hagberg

    Rett's syndrome: prevalence and impact on progressive severe mental retardation in girls

    Acta Paediatr

    (1985)
  • C.A Kozinetz et al.

    Epidemiology of Rett syndrome: a population-based registry

    Pediatrics

    (1993)
  • B Hagberg

    Rett syndrome—clinical and biological aspects

    (1993)
  • R Amir et al.

    Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

    Nat Genet

    (1999)
  • Rett Syndrome Diagnostic Criteria Work Group

    Diagnostic criteria for Rett syndrome

    Ann Neurol

    (1988)
  • R.J Schultz et al.

    The pattern of growth failure in Rett syndrome

    Am J Dis Child

    (1993)
  • B Hagberg et al.

    Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence

    Am J Med Genet

    (1986)
  • B Hagberg et al.

    “Forme fruste” of Rett syndrome—a case report

    Am J Med Genet

    (1986)
  • J Aicardi

    Rett syndrome

    Int Pediatr

    (1988)
  • K Hoffbuhr et al.

    MeCP2 mutations in children with and without the phenotype of Rett syndrome

    Neurology

    (2001)
  • H Leonard et al.

    Occurrence of Rett syndrome in boys

    J Child Neurol

    (2001)
  • J.S Schwartzman et al.

    Rett syndrome in a boy with a 47,XXY karyotype

    Am J Hum Genet

    (1999)
  • S.G Vorsanova et al.

    Cytogenic and molecular-cytogenic investigation of Rett syndrome: analysis of 31 cases

    Neuroreport

    (1996)
  • N.C Schanen et al.

    Neonatal encephalopathy in two boys in families with recurrent Rett syndrome

    J Child Neurol

    (1998)
  • L Villard et al.

    Two affected boys in a Rett syndrome family: clinical and molecular findings

    Neurology

    (2000)
  • J Armstrong et al.

    Classic Rett syndrome in a boy as a result of somatic mosaicism for a MECP2 mutation

    Ann Neurol

    (2001)
  • B Imessaoudene et al.

    MECP2 mutation in non-fatal, non-progressive encephalopathy in a male

    J Med Genet

    (2001)
  • M Vacca et al.

    Mutation analysis of the MECP2 gene in British and Italian Rett syndrome females

    J Mol Med

    (2001)
  • S.S Budden

    Rett syndrome: habilitation and management reviewed

    Eur Child Adolesc Psychiatry

    (1997)
  • D Glaze et al.

    Rett's syndrome: correlation of electroencephalographic characteristics with clinical staging

    Arch Neurol

    (1987)
  • U Steffenburg et al.

    Epilepsy in a representative series of Rett syndrome

    Acta Paediatr

    (2001)
  • Y Stenbom et al.

    Lamotrigine in Rett syndrome: treatment experience from a pilot study

    Eur Child Adolesc Psychiatry

    (1998)
  • Cited by (0)

    Supported in part by the International Rett Syndrome Association.

    View full text